JP Morgan Chase
KALA icon

JP Morgan Chase’s KALA BIO KALA Stock Holding History

JP Morgan Chase’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1
Closed -$20K – 5537
2020
Q1 		$20K Buy
+1
New +$16K ﹤0.01% 4951

Other funds holding KALA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JP Morgan Chase's KALA Position: Q2 2026 in Review

JP Morgan Chase sold out of KALA BIO (KALA) in Q2 2026, closing a stake of 600 shares — an estimated $5.13K sold.

JP Morgan Chase first reported a position in KALA in Q3 2017 and held it in 35 quarters. The position peaked at $4.15M in Q4 2017. 14 funds tracked by Wall St. Rank hold KALA as of Q2 2026.

  • JP Morgan Chase reported no remaining KALA BIO position as of Q2 2026 after selling out during the quarter.
  • JP Morgan Chase sold 600 KALA BIO shares in Q2 2026, an estimated $5.13K.
  • JP Morgan Chase first reported a position in KALA BIO in Q3 2017 and held it in 35 quarters.
  • JP Morgan Chase's KALA BIO position peaked at $4.15M in Q4 2017.
  • 14 funds tracked by Wall St. Rank held KALA BIO as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.